Javara and Ogden Clinic Launch Trial Access Partnership
Javara and Ogden Clinic have announced the launch of a partnership to integrate industry-sponsored clinical trials at the point of care for Ogden Clinic patients. Through this partnership, Javara will enable access to clinical trials for patients throughout the Ogden Clinic network by providing services to support and conduct research. The Ogden Clinic currently spans 20 locations in northern Utah and includes 171 practitioners across 24 specialties.
Javara will embed clinical research infrastructure and site staff, led by Javara’s Clinical Trial Navigators, who will work alongside the practitioners and medical staff to scale clinical trial operations. Javara and Ogden Clinic anticipate early clinical trials in general medicine, pediatrics, and dermatology, with initial trials expected to begin in 4th quarter of 2021.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
